微生物组治疗市场增长、规模、份额、趋势、关键参与者分析及 2030 年预测

  • Report Code : TIPRE00027698
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 160
Buy Now

 

[研究报告] 微生物组治疗市场规模预计将从 2022 年的 3.7592 亿美元增长到 2030 年的 8.1338 亿美元;预计 2022 年至 2030 年的复合年增长率为 10.1%。

 

市场洞察和分析师观点:

微生物组疗法,也称为基于微生物组的疗法或干预,是利用人类微生物组的潜力治疗各种疾病的医疗程序。在医疗保健和生命科学行业,微生物组疗法是一个新兴且快速扩张的市场。微生物组研究的进步推动了这一市场的发展,提高了人们对肠脑联系的认识,并为开发一系列疾病的尖端疗法提供了可能性。微生物组疗法的渠道充满活力且多种多样,旨在解决广泛的疾病问题并提供利用人类微生物组的新型治疗方法。随着这一研究领域的发展,可能会出现更多基于微生物组的治疗方法,为市场扩张开辟新的途径。由于代谢紊乱、肥胖、肠易激综合征和炎症性肠病等疾病的患病率不断上升,对新型和更有效的治疗方法的需求日益增长。基于微生物组的治疗方法是治疗这些疾病的尖端方法。这为不久的将来微生物组治疗市场扩张创造了巨大的机会。

 

增长动力和挑战:

微生物组疗法旨在通过使用噬菌体、细菌素、抗生素、天然或合成细菌或减法或调节疗法来改变肠道微生物组。通过提供个性化、协调、可靠和持久的治疗,该策略可以克服传统疗法的局限性。全球治疗市场已展示出其巨大的经济潜力。研究表明,使用微生物组疗法治疗炎症性肠病、肥胖症甚至精神健康障碍等疾病具有良好的效果。正在进行的研究也在探索基于微生物组的干预措施在癌症治疗、糖尿病管理和心血管健康领域的潜力。此外,胃肠道疾病的发病率随着年龄的增长而增加,2021 年 2 月的 GI Alliance 数据估计,近 2000 万美国人患有慢性消化系统疾病,每年有超过 6200 万美国人被诊断出患有胃肠道疾病。国际胃肠道疾病基金会(IFFGD)公布的统计数据显示,GERD在北美的发病率为18%-28%,在南美为23%,在欧洲为9-26%。因此,在未来几年,胃肠道疾病的发病率增加将推动市场扩张。

通过了解微生物组与疾病发展之间的复杂关系,科学家们正在开发针对问题根源而非仅仅控制症状的个性化治疗方法。随着知识的扩展和技术的进步,微生物组疗法有可能成为现代医学的基石,为受各种疾病影响的个体改善健康状况带来希望。

技术进步促进了有针对性干预措施的发展。通过了解与某些疾病或病症相关的特定微生物物种,研究人员可以开发专门针对这些微生物的疗法。与传统的广谱抗生素相比,这种个性化方法可能更有效,副作用更少。除了测序技术的进步外,其他技术创新也促进了微生物组疗法的发展。此外,合成生物学工具的开发也取得了进展,这些工具可以设计具有所需功能的微生物群落。这为设计可针对个体患者的基于微生物组的疗法开辟了新的可能性。

识别和分离特定有益微生物以及大量生产这些微生物的过程可能既昂贵又耗时。此外,确保这些疗法的安全性和有效性需要严格的测试和监管部门的批准,这进一步增加了成本。微生物组疗法的个性化性质又增加了另一层复杂性和成本。每个人的微生物组都是独一无二的,这意味着治疗可能需要根据他们特定的微生物组成进行量身定制。这需要大量的分析和测试,这既费钱又费时,从而阻碍了微生物组疗法市场的增长。

 

定制此报告以满足您的需求

您可以免费定制任何报告,包括本报告的部分内容、国家级分析、Excel 数据包,以及为初创企业和大学提供优惠和折扣

微生物组治疗市场: Therapeutics Market:

Microbiome Therapeutics Market
  • 获取此报告的关键市场趋势。
    这个免费样品将包括数据分析,从市场趋势到估计和预测。

 

报告细分和范围:

微生物组治疗市场根据类型、应用和最终用户进行划分。根据类型,微生物组治疗市场细分为治疗方法和程序。根据应用,微生物组治疗市场细分为代谢紊乱和肥胖症、艰难梭菌感染和炎症性肠病。就最终用户而言,微生物组治疗市场分为医院和诊所、门诊手术中心和家庭护理。根据地理位置,微生物组治疗市场分为北美(美国、加拿大和墨西哥)、欧洲(英国、德国、法国、意大利、西班牙和欧洲其他地区)、亚太地区(中国、日本、印度、韩国、澳大利亚和亚太其他地区)、中东和非洲(阿联酋、沙特阿拉伯、南非和中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷和南美洲和中美洲其他地区)。

 

节段分析:

根据类型,微生物组治疗市场细分为治疗和程序。粪便微生物组治疗技术是一种新兴技术,已被证明对复发性艰难梭菌感染 (CDI) 患者非常有效。美国食品药品管理局 (FDA) 批准用于预防 CDI 复发的 FMT 产品越来越多,这推动了该细分市场的增长。例如,2022 年 11 月,美国 FDA 批准了 Rebyota,这是第一种用于预防 18 岁以上人群 CDI 复发的粪便微生物组产品。

根据应用,微生物组治疗市场分为代谢紊乱和肥胖症、艰难梭菌感染、炎症性肠病等。2022 年,艰难梭菌感染细分市场占据了最大的市场份额,预计在 2022-2030 年期间将实现最高的复合年增长率。当有人服用抗生素时,肠道中的有益细菌会被破坏几个月。在此期间,患者可能会因艰难梭菌而生病,这种细菌通常会导致严重甚至致命的腹泻。根据 CDC 的数据,2021 年,美国约有 118,000 名住院患者患有艰难梭菌感染。为了预防和治疗艰难梭菌感染,需要通过给予微生物组治疗来增加患者的肠道微生物组。由于艰难梭菌感染数量的增加,公司正专注于开发用于治疗的微生物组疗法。例如,2023年4月,美国FDA批准了第一个用于预防艰难梭菌感染复发的粪便微生物群Vowst。

根据最终用户,微生物组治疗市场分为医院和诊所、门诊手术中心、家庭护理和其他。2022 年,医院和诊所部门占据了最大的市场份额,预计在 2022-2030 年期间将实现最高的复合年增长率。医院是微生物组治疗市场增长最快的最终用户。医院是患者寻求急救和治疗的主要医疗中心。与其他医疗中心相比,去医院就诊的患者数量相对较高。这些中心提供各种服务,并为患者提供高质量的治疗。在许多医院,治疗费用是可以报销的;此外,这些医疗中心的药品也随时可用。医院实施先进的治疗技术为改善和早期发现疾病以及支持与疾病治疗相关的研究铺平了道路。由于治疗费用的可负担性和人们的认识不断提高,医疗服务越来越多。它是许多国家生态系统的一部分,因为它对该国的 GDP 增长做出了重大贡献。

 

 

微生物组治疗市场区域洞察

Insight Partners 的分析师已详细解释了预测期内影响微生物组治疗市场的区域趋势和因素。本节还讨论了北美、欧洲、亚太地区、中东和非洲以及南美和中美洲的微生物组治疗市场细分和地理位置。

Microbiome Therapeutics Market
  • 获取微生物组治疗市场的区域特定数据

微生物组治疗市场报告范围

报告属性细节
2022 年市场规模3.7592亿美元
2030 年的市场规模8.1338亿美元
全球复合年增长率(2022 - 2030 年)10.1%
史料2020-2021
预测期2023-2030
涵盖的领域按类型
  • 治疗和程序
按应用
  • 代谢紊乱与肥胖
  • 艰难梭菌感染
  • 炎症性肠病
按最终用户
  • 医院和诊所
  • 门诊手术中心
  • 家庭护理
覆盖地区和国家北美
  • 我们
  • 加拿大
  • 墨西哥
欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
亚太
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
市场领导者和主要公司简介
  • 肠内科
  • 芬奇治疗集团公司
  • 凯勒斯健康
  • 辉凌制药
  • Pendulum Therapeutics 公司
  • AO生物群落
  • Seres 治疗公司
  • 韦丹塔生物科学公司
  • COST-BRY 有限公司 (BiomeBank)

 

微生物组治疗市场参与者密度:了解其对业务动态的影响

微生物组治疗市场正在快速增长,这得益于终端用户需求的不断增长,这些需求源于消费者偏好的不断变化、技术进步以及对产品优势的认识不断提高等因素。随着需求的增加,企业正在扩大其产品范围,进行创新以满足消费者的需求,并利用新兴趋势,从而进一步推动市场增长。

市场参与者密度是指在特定市场或行业内运营的企业或公司的分布情况。它表明在给定市场空间中,相对于其规模或总市场价值,有多少竞争对手(市场参与者)存在。

在微生物组治疗市场运营的主要公司有:

  1. 肠内科
  2. 芬奇治疗集团公司
  3. 凯勒斯健康
  4. 辉凌制药
  5. Pendulum Therapeutics 公司

免责声明上面列出的公司没有按照任何特定顺序排列。


Microbiome Therapeutics Market

 

  • 了解微生物组治疗市场顶级关键参与者概况

 

 

区域分析:

 

根据地域划分,微生物组治疗市场分为北美、欧洲、亚太地区、中东和非洲以及南美和中美。北美是微生物组治疗市场增长的最大贡献者。人们越来越认识到人类微生物组在维持健康和预防疾病方面的重要性,这促使美国研究人员探索基于微生物组的干预措施,将其作为治疗各种疾病的有前途的方法。此外,美国在微生物组治疗市场的主导地位主要归功于其完善的研究基础设施,有利于创新治疗方法的开发。基因测序和生物信息学的技术进步使得微生物组的研究和改变成为可能,促进了个性化微生物组干预措施的开发。个性化医疗的趋势与量身定制的微生物组疗法相一致。学术界、工业界和政府组织之间的合作也推动了研发工作,加速了科学发现转化为商业产品。该领域的监管支持和投资进一步促进了市场增长,因为监管机构认识到微生物组疗法的潜力并为其开发和批准提供指导。对研究和创新的重视使人们对肠道微生物群对健康的影响有了深刻的了解,为基于微生物组的疗法奠定了坚实的基础。加拿大对生物技术和制药的支持性监管环境鼓励公司投资于以微生物组为重点的研究和开发。此外,风险投资和政府资金的增加也为这项研究注入了资金。2020 年 1 月,加拿大政府及其合作伙伴为关键的微生物组研究投资了 1800 万美元。

预计亚太地区将成为未来几年增长最快的市场。由于人们对人体微生物组对健康的影响的认识和研究不断增加,日本的微生物组治疗市场正在经历显著增长。这促使制药和生物技术公司投资基于微生物组的疗法。日本人口老龄化以及与年龄相关的疾病(包括胃肠道问题和代谢疾病)的增加,对新型治疗方案产生了强烈的需求。微生物组疗法具有提供个性化和有效解决方案的潜力,非常适合应对这些医疗保健挑战。此外,有利的监管环境和政府支持微生物组研发的举措对日本微生物组治疗市场的增长起着至关重要的作用。

 

竞争格局和重点公司:

 

Enterome、Finch Therapeutics Group Inc、Caelus Health、Ferring Pharmaceuticals、Pendulum Therapeutics Inc.、AOBiome、Seres Therapeutics、Vedanta Biosciences、COST-BRY Pty Ltd (BiomeBank) 和 YSOPIA Bioscienceare 是微生物组治疗市场中的几家知名企业。这些公司专注于扩大服务范围,以满足全球日益增长的消费者需求。它们的全球影响力使它们能够服务于大量客户,从而扩大其市场份额。

  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What factors drive the microbiome therapeutics market?

The gut microbiota in maintaining human health and inflow of funds to ameliorate microbiome discovery pipeline bolster the microbiome therapeutics market size. However, the high cost of development and production hinders the microbiome therapeutics market growth.

What is microbiome therapeutics?

Microbiome therapeutics, also referred to as microbiome-based therapies or interventions, are medical procedures that try to use the human microbiome's potential to treat and promote a variety of illnesses. In the healthcare and life science industries, microbiome therapeutics are a new and quickly expanding market. This market is being driven by advancements in microbiome research, which are raising awareness of the gut-brain connection and offering the possibility of developing cutting-edge treatments for a range of medical conditions.

Which type segment dominates the microbiome therapeutics market?

Fecal microbiome therapeutic technique is an emerging technique that has proven to be highly effective in patients with recurring Clostridioides difficile infection (CDI). Growing FMT product approvals by the Food and Drug Administration (FDA) for preventing the recurrence of CDI is fueling the growth of the segment. For instance, in November 2022, the US FDA approved Rebyota, the first fecal microbiota product used for the prevention of CDI recurrence in individuals aged above 18 years.

What are the growth estimates for the microbiome therapeutics market till 2030?

The microbiome therapeutics market is expected to be valued at US$ 813.38 million in 2030.

What was the estimated microbiome therapeutics market size in 2022?

The microbiome therapeutics market was valued at US$ 375.92 million in 2022.

Who are the major players in the microbiome therapeutics market?

The microbiome therapeutics market has major market players, including Enterome, Finch Therapeutics Group Inc, Caelus Health, Ferring Pharmaceuticals, Pendulum Therapeutics Inc., AOBiome, Seres Therapeutics, Vedanta Biosciences, COST-BRY Pty Ltd (BiomeBank) and YSOPIA Bioscience.

Which end user segment dominates the microbiome therapeutics market?

In 2022, the hospitals and clinics segment held the largest share of the market, and it is expected to register the highest CAGR during 2022–2030. Hospitals are the fastest-growing end users of the microbiome therapeutics market. Hospitals are the primary healthcare centers patients seek for their first aid and treatment. The number of patients visiting hospitals is comparatively higher than other healthcare centers. These centers offer various services and provide good-quality treatment to patients. In many hospitals, the treatment fee is reimbursed; also, medicines are readily available in these healthcare centers. The implementation of advanced treatment technologies in hospitals has paved the way for improved and early detection of disease, as well as supported research related to disease treatment..

Which application type segment dominates the microbiome therapeutics market?

In 2022, the C. difficile infection segment held the largest share of the market and is expected to register the highest CAGR during 2022–2030. When someone takes antibiotics, good bacteria in the gut are destroyed for a few months. During this time, patients can get sick from Clostridioides difficile, a bacteria that often causes severe or even deadly diarrhea. According to CDC, in 2021, ~118,000 hospitalized patients suffered from C. difficile infection in the US. To prevent and treat C. difficile infection, the gut microbiome of the patient needs to be increased by giving microbiome therapeutics. Due to the increase in the number of C. difficile infections, companies are focusing on developing microbiome therapeutics for the treatment. For instance, in April 2023, the US FDA approved Vowst, the first fecal microbiota used to prevent the recurrence of C. difficile infection.

Trends and growth analysis reports related to Life Sciences : READ MORE..   
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

The List of Companies - Microbiome Therapeutics Market 

  1. Enterome
  2. Finch Therapeutics Group Inc
  3. Caelus Health
  4. Ferring Pharmaceuticals
  5. Pendulum Therapeutics Inc.
  6. AOBiome
  7. Seres Therapeutics
  8. Vedanta Biosciences
  9. COST-BRY Pty Ltd (BiomeBank)
  10. YSOPIA Bioscienceare

Buy Now  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.